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1INTRODUCTION
           Chronic inflammation has been implicated as predictor and
contributor of aging and age associated diseases. Inflammation involves
elevation of serum inflammatory markers such as C-Reactive protein,
interleukin-6.
        Association of cardiovascular diseases and elevated level of
inflammatory markers is well known. Many studies have demonstrated
the association of elevated level of inflammatory markers in
cardiovascular diseases. Absence of vascular disease has been
established as a major determinant of longevity.
        Recent studies have shown elevated level of serum inflammatory
markers such as Interleukin-6, C-reactive protein in diseases primarily
associated with aging like Coronary heart disease, diabetes mellitus,
systemic hypertension, stroke, Dementia, Frailty, Osteoarthritis,
Osteoporosis, Cancer, Rheumatoid Arthritis.
          Frailty is a syndrome of age associated decline in physiological
reserve , and has been associated with chronic inflammation. Recent
2studies have shown elevated level of serum inflammatory markers in
frailty and adverse health outcome.
        Serum inflammatory markers may well evolve in to a more usefull
clinical tool that can help to identify the most vulnerable elders and
guide preventive intervention.
           In this study, the association of inflammatory marker in the sub
groups namely  healthy elders, frail elders and elders with comorbid
illness will be analysed.
3AIM OF THE STUDY
1. To Compare the level of inflammatory markers Interleukin-6,
High-sensitivity C-Reactive protein in elderly patients
i)     Healthy elders (without comorbid elders)
ii)    Frail elders
 iii)  With comorbid illness
2.  To correlate the role of  Infammatory markers in Aging.
3.  To analyse whether elevated level of inflammatory markers could
be used in predicting  the risk of  aging in elders,  with a view of
primary prevention.
4MATERIALS AND METHODS
Setting
Outpatient   and   Inpatient  setting  of  the  Department  of  Geriatric
Medicine, Madras Medical College & Government General Hospital,
Chennai.
Study Design
Single Center, Cross Sectional, clinical and analytical study
Period of study
August 2008 to September 2010.
Sample size
90
Selection of patients
Inclusion criteria
90 elderly patients age more than 75years from Geriatric
outpatient and inpatient Department are included in the study.
5Exclusion criteria
1. Acutely toxic patients
2. Rheumatoid arthiritis,  chronic liver disease, Multiple myeloma,
Proliferative diseases like psoriasis,  mesangial proliferative
glomerulonephritis.
Analysis
Data analysed using statistical package SPSS software
Details of the study
        90 patients age more than 75years from Geriatic outpatient and
Inpatient Department were enrolled.
The study subjects enrolled in three following  sub groups:
i)  30 patients without comorbid elders ( Healthy elders)
    ii)  30 Frail elders according to Fried’s criteria
 iii) 30  patients  with  comorbid  illness  (DM,  SHT,  CHD,
CVA, Dementia)
       All the study subjects were interview during their first visit and
medical history obtained. This included their name, age, sex, OP/IP no.,
presenting complaints.  History of comorbid illness and duration of
6illness  (  DM,  SHT,  CHD,  CVA,  Dementia  )  and  medication  used.
History of  substance abuse like tobacco smoking and alcohol, duration
of abuse.
           The patients were explained of the methods and objectives of the
study and an informed consent was obtained. A detailed general
examination was carried out that included pulse rate, blood pressure.
Systemic examination was done.
         In all patients Mini Mental Score Examination was  done. Patients
having score less than 24 is considered as having dementia. Patients
educational status was enrolled.
         Patients with frailty are categorized according to “FRIED’S
criteria of frailty” which includes:
1.Gait speed
2.Hand grip strength
3.Weight loss
4.Physical activity
5.Self reported physical exhaustion
Score:  0 = No frailty
            1 &2 = Prefrail
            3 and above = frailty
7The following investigation  were done in all sub groups ESR,
hemoglobin, blood sugar, serum urea and creatinine, lipid profile,
Interleukin 6 level was measured by ELISA method and High-
sensitivity C- Reactive protein by Immunoturbidimetry method, 12 lead
ECG, CXR-PA, CT Brain if available are documented.
High-sensitivity C- Reactive protein by Immunoturbidimetry
method.
Mode of reaction Fixed time
Slope of reaction Increasing
Wavelength 546nm
Temperature 37º  C
Calibrator concentration 63 mg/L
Delay time 5 sec
Time interval 120 sec
Sample volume 2.5µl
Reagent volume 500µl
Cuvette path length 1cm light path
Method Immunoturbidimetry method.
Normal range Serum up to 6.0mg/L
8Human IL-6 ELISA method
Preparation of standard = 200 ?g/ml
Serial dilution for the stock standard = (using standard diluents
buffer)
Stock standard  200 pg/ml           1 in 1 dilution = 100 pg/ml
                          100 pg/ml          1 in 1 dilution = 50 pg/ml
                          50 pg/ml            1 in 1 dilution = 25 pg/ml
                          25 pg/ml            1 in 1 dilution = 12.5 pg/ml
                          12.5 pg/ml         1 in 1 dilution = 6.25 pg/ml
Note:
1 in 1 dilution means take equal parts of standard and standard
diluents buffer.
9Test Protocol for Human IL-6
100 ul of sample / diluted standards / water for zero concentration +
Add 50 ul of diluted Biotinylated anti IL-6 antibody reagent
                                               Incubate at room temperature for 1 hr
       Wash after 1 hr using wash buffer (4-5 times)
     Add 100 ul of diluted Streptavidin HRP solution(conjugate)
                                               Incubate at room temperature for 30 min
    Wash after 30 min using wash buffer (4-5 times)
    Add 10 ul of TMB substrate solution (chromogen)
Incubate in dark at room temperature for
10-15 min
     Add 100 ul of H2 SO4 (stop solution)
      Take reading at 450nm (620nm as a differential filter)
       Result: Expected serum values less than 2 ?g/ml
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REVIEW OF LITERATURE
INFLAMMATION AND AGEING
            Ageing is accompanied by 2-4 fold increases in  serum levels of
inflammatory mediators, such as cytokines and acute-phase proteins1.
          The term "Inflammaging" has been coined by Claudio Franceschi
to explain the now widely accepted phenomenon that ageing is
accompanied by a low-grade chronic, systemic up-regulation of the
inflammatory response and that the underlining inflammatory changes
are also common to most age-associated diseases2-9.
        Inflammation has been classically characterized by the cardinal
signs of heat, pain, swelling and redness. But inflammation also operates
at  a  much  lower  level.  This  marks  a  shift  from  the  old  view  of
inflammation ( either present or absent) to the new ( always “present”
but to varying degrees)10.
         Acute inflammation is well known to be associated with the five
cardinal features 1. rubor (redness), 2. tumor (swelling), 3. dolor (pain),
4. calor (warm), 5. functio lesa (loss of function).  on the contrary,
inflammaging is characterized by the complex set of five features which
11
can be described as 1. low-grade, 2. controlled, 3. asymptomatic, 4.
chronic, 5. systemic, inflammatory state.
         In most superifical process, inflammation is localized and does
not usually result in a measurable systemic reponse. However in major
infection or injuries, systemic activation of inflammatory pathways
result in measurable elevations in circulating inflammatory cytokines
and other acute phase reactant proteins11.
           Inflammation involves systemic markers  often liver proteins
such as CRP and fibrinogen, paracrine / endocrine local markers such as
IL- 6 and TNF?, and cell-cell interaction markers such as E-selectin and
intercellular adhesion molecule-1.
          Inflammation involves a cascade in which tissue injury stimulates
cells to make pro-inflammatory cytokines, which in turn stimulate
hepatocytes to produce acute  phase proteins and inflammatory markers.
        Aging has also been associated with increased levels of circulating
inflammatory components in the blood including elevated
concentrations of TNF-alpha, IL-6, acute-phase proteins such as
C-reactive protein and serum amyloid A, and high neutrophil counts.
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         This increase, however, in circulating inflammatory parameters in
healthy elderly humans is small and far less than levels seen during
acute infections.
          A wide range of factors seems to contribute to this low-grade
inflammation, including an increased amount of fat tissue, decreased
production of sex steroids, smoking, subclinical infections  such as
Chlamydia pneumonia,  Helicobacter pylori,  dental infections and
asymptomatic bacteriuria may play a role  and such chronic disorders as
cardiovascular diseases and Alzheimer’s disease.
         Aging itself is associated with complex changes in the immune
system. There is a progressive increase in the concentration of
glucocorticoids and catecholamines with aging, and decreased
production of growth and sex hormones, a pattern suggestive of that
seen in chronic stress.
        The inflammatory scenario that characterizes inflammaging
constitutes a highly complex response to various subtle internal and
environmental inflammatory stimuli mediated mainly by the increased
circulating levels of pro inflammatory cytokines. Inflammaging also
generates Reactive Oxygen Species (ROS) causing both oxidative
13
damage and eliciting an amplification of the cytokines  release, thus
perpetuating a vicious cycle resulting in a chronic systemic pro
inflammatory state where tissue injury and healing mechanisms proceed
simultaneously and damage slowly accumulates asymptomatically over
decades and is a major determinant both of the ageing process and of
the development of age-associated diseases .
           Inflammaging is triggered by the first line of biological defense
i.e. the innate immunity that operates by detection of a broad range of
injuries inducing the activation of inflammatory responses. The
mononuclear phagocytes lineage plays a pivotal role in innate immunity
that does not require clonal expansion of cell populations . Moreover,
several other cell types contribute to innate immunity by expressing
pattern recognition receptors, namely various scavenger and Toll like
receptors . These cell encoded proteins recognize ligands from damaged
tissues and induce host responses by transmembrane signals that activate
NFkB and mitogen dependent protein kinase pathway . Toll like
receptor activation also induces the expression of a wide variety of
number of genes encoding proteins, such as cytokines, with regulatory
functions upon cell activations and tissue inflammation .
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Inflammaging as a summary of the physiological and molecular
changes  consistent  with  the  aging  process  that  are  known  to  be
associated with chronic activation of inflammatory pathways11.
Normal inflammatory response to injury or infection. With
activation  of multiple physiological pathways and ultimately
resolution  of response.
Inflammatory cytokines    Thrombotic pathways      SNS/ HPA axis
     activation
     Injury
        &
  Infection
     Innate immune system activation
Resolution and Deactivation of inflammation
Negative
feedback molecules
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      H2O2              TNF ?               IL-1               LPS             Thrombin
       IL-6                      IL-8                           MCP-1                      COX-2
CRP, STAT-3     Neutrophil attractant    Monocyte attractant      Prostaglandin
Schematic of the inflammatory gateway nuclear transcription
factor  NF?B,  along  with  inflammatory  triggers  (row  A),  and
inflammatory outflow (rows B and C). Row A shows specific
inflammatory stimuli that lead to NF?B activation via specific cell
receptors and specific signal transduction pathways (not shown).
Activated subunits of  NF?B in turn leads to the expression of proteins
that provide negative feedback for inflammation (not shown) or that
propagate inflammatory message (row B) and influence the activation of
other pathways (row C) that influence inflammatory  response,
thrombosis and the expression of other proteins.
  NF?B
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           Aging is associated with a dysregulated cytokine response
following stimulation. Cytokines are potent anorectic agents. Many
older persons have mild inflammatory disorders that lead to anorexia12.
cytokines play a role in the pathogenesis of anorexia and sarcopenia,
thus accelerating the development of frailty in older persons13.
        Increased cerebral secretion of cytokines due to a wide range of
physically stressful events plays an important role in the occurrence of
delirium14.
         Increased IL-6 levels leads to loss of muscle and bone mass,
fever, activation of the hypothalamic-pituitary-adrenal axis, activation of
the hepatic acute-phase response, and hemodilution resulting in a
decline in hemoglobin levels15-18.
        In bone, IL-6 is produced by osteoblasts and promotes osteoclast
activity and subsequent bone resorption19. Numerous acquired
influences such as  visceral obesity, smoking, stress also trigger IL-6
release.
          IL-6 and CRP associated with adverse health outcomes and
disease states in older adults11. In older persons, CRP has been shown to
be a marker of functional decline and mortality20-23
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Cigarette smoking has been shown to promote higher
levels of IL-6. Exercise may be an efficacious therapy for restoring
immune function in the elderly. Long-term exercise interventions appear
to be promising.
          Serum inflammatory markers may well evolve into a more useful
clinical tool that can help identify the most vulnerable older adults and
guide therapeutic or preventive interventions11.
The basic steps to reduce inflammation in the body include:
? Better dental hygiene -  Low grade gum infections are extremely
common and have a major negative impact on heart disease.
? Exercise - Evidence indicates that regular exercise improves low
grade chronic inflammation. It may worsen acute or active
chronic inflammation.
? Weight loss - Obesity appears to increase the overall level of
inflammation in the body.
? No smoking - Smoking floods the  systems with free radicals and
irritants, promoting inflammation and other forms of damage.
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? Anti-inflammatory diet - Diet has an impact on the overall level
of inflammation in  body. A number of dietary adjustments can
help minimize inflammation, including the following: reducing or
eliminating saturated and trans fat; increasing the intake of
omega-3 fat (fish, fish oil, flaxseed oil); increasing consumption
of  fruits and vegetables. Anti-inflammatory diet should be high in
fiber and favor low glycemic foods. Research indicates that
animal protein may be somewhat proinflammatory. To reduce
inflammation, use  protein from non-animal sources like fish, soy,
beans and nuts.
? Drugs
COX- inhibitors e.g. aspirin
Statins e.g. lipitor
Proteases  e.g. serrapepditase, nattokinase, bromelain
LOX-inhibitors  e.g. acetyl-boswellic acid.
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C-reactive protein (CRP)
CRP  is  a  protein  found  in  the  blood,  the  levels  of  which  rise  in
response to inflammation  an acute-phase protein.  Its physiological role
is to bind to phosphocholine expressed on the surface of dead or dying
cells (and some types of bacteria) in order to activate the complement
system via the C1Q complex24.
CRP is synthesized by the liver25 in response to factors released
by fat cells (adipocytes).26  It  is  a  member  of  the  pentraxin  family  of
proteins.25 It is not related to C-peptide or protein C.
History and nomenclature
CRP was originally discovered by Tillett and Francis in 1930 as a
substance in the serum of patients with acute inflammation that reacted
with the C polysaccharide of pneumococcus.27 Initially it was thought
that CRP might be a pathogenic secretion as it was elevated in people
with a variety of illnesses including cancer,25 however discovery of
hepatic synthesis demonstrated that it is a native protein.
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Function
CRP is a member of the class of acute-phase reactants, as its
levels rise dramatically during inflammatory processes. This increment
is due to a rise in the plasma concentration of IL-6, which is produced
predominantly by macrophages25 as well as adipocytes.  CRP  binds  to
phosphocholine on microbes. It is thought to assist in complement
binding to foreign and damaged cells and enhances phagocytosis by
macrophages, which express a receptor for CRP.
        CRP rises up to 50,000-fold in acute inflammation, such as
infection.  It  rises  above  normal  limits  within  6  hours,  and  peaks  at  48
hours. Its half-life is constant, and therefore its level is mainly
determined by the rate of production and hence the severity of the
precipitating cause. Serum amyloid A is a related acute-phase marker
that responds rapidly in similar circumstances.25
Diagnostic use
CRP is used mainly as a marker of inflammation. Apart from liver
failure, there are few known factors that interfere with CRP
production.25
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Measuring  CRP values can prove useful in determining disease
progress or the effectiveness of treatments.  Blood, usually collected in a
serum-separating tube, is analysed in a medical laboratory.  Various
methods are available for CRP determination, such as ELISA,
immunoturbidimetry, rapid immunodiffusion, and visual agglutination.
When to start testing CRP
Elevated C-Reactive Protein levels provide information on
cardiovascular risk over the age of  30-40 years.  Can detect risk years in
advance and have the opportunity to initiate lifestyle and pharmacologic
interventions in order to prevent heart attack or stroke.
High-sensitivity CRP test (hs-CRP)
hsCRP measures low levels of CRP using laser nephelometry.
The test gives results in 25 minutes with a sensitivity down to
0.04 mg/L. Normal concentration in healthy human serum is usually
lower than 10 mg/L, slightly increasing with ageing. Higher levels are
found in late pregnant women, mild inflammation and viral infections
(10–40 mg/L), active inflammation, bacterial infection (40–200 mg/L),
severe bacterial infections and burns (>200 mg/L)28
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Difference between regular CRP and hs-CRP tests
Both tests measure the same molecule in the blood. The hs-CRP
test is to determine the  risk of cardiovascular disease. It measures CRP
in the range from 0.5 to 10 mg/L.  The CRP is  done in  patients  at  risk
for bacterial or viral infection,  patients with chronic inflammatory
diseases (such as rheumatoid arthritis). It measures CRP in the range
from 10 to 1000 mg/L.
Conditions that lower CRP levels
Lliver disease, weight loss, exercise, moderate alcohol intake, and
lipid lowering agents that  inhibit hepatic hydroxyl methyl glutaryl
coenzyme A.
Cardiology diagnostic test
Arterial  damage  results  from  white  blood  cell   invasion  and
inflammation within the wall. CRP is a general marker for inflammation
and infection, so it can be used as a very rough proxy for heart disease
risk. Since many things can cause elevated CRP, this is not a very
specific  prognostic indicator.29
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Role in cardiovascular disease
AHA/CDC risk assessment guidelines30 (American Heart
Association and Centers for Disease Control & Prevention)
Low risk <1 mg/L
Average risk 1-3 mg/L
High risk >3 mg/L
In  the  capture  trail,  CRP  levels  of   >10mg/L  doubled  the  event
rate (mortality or MI), compared to CRP levels of <10mg/L.
Recent research suggests that patients with elevated basal levels
of CRP are at an increased risk of diabetes,31,32 hypertension and
cardiovascular disease.
Treatment to lower CRP
 Lowering C-Reactive Protein  will result in a direct lowering of
cardiovascular risk. CRP is lowered by diet, exercise, blood pressure
control and quiting  smoking.
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The JUPITER trial was conducted to determine if patients with
elevated CRP levels but without hyperlipidemia might benefit from
statin therapy. Statins were selected because they have been proven to
reduce levels of CRP2 . The trial found that patients taking rosuvastatin
with elevated CRP levels experienced a decrease in the incidence of
major cardiovascular events33. The trial specifically found,  after four
years of treatment, out of every 31 patients, one cardiovascular event
would be prevented.
Interleukin-6
 Interleukin-6  is a protein that in humans is encoded by the IL6
gene. 34 IL-6 is an interleukin that acts as both a pro inflammatory and
anti inflammatory cytokine. It is secreted by T cells and macrophages to
stimulate immune response to trauma, especially burns or other tissue
damage leading to inflammation. In terms of host response to a foreign
pathogen, IL-6 has been shown  in mice, to be required for resistance
against the bacterium, Streptococcus pneumoniae.35
 IL-6 is also a "myokine," a cytokine produced from muscle, and
is elevated in response to muscle contraction.36 It is significantly
elevated with exercise, and precedes the appearance of other cytokines
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in the circulation. During exercise, it is thought to act in a hormone-like
manner to mobilize extracellular substrates and augment substrate
delivery (Petersen, J Appl Physiology  2005).
Osteoblasts secrete IL-6 to stimulate osteoclast formation.
Smooth muscle cells in the tunica media  of many blood vessels also
produce  IL-6  as  a  pro-inflammatory  cytokine.   IL-6's  role  as  an  anti-
inflammatory cytokine is mediated through its inhibitory effects on
TNF-alpha and IL-1, and activation of IL-1ra and IL-10.
A  cytokine for gerontologists37.
Interleukin-6  is a proinflammatory cytokine that is normally
tightly regulated and expressed at low levels, except during infection,
trauma, or other stress38,39.
         Among several factors that down-regulate IL-6 gene expression
are estrogen and testosterone. After menopause or andropause, IL-6
levels are elevated, even in the absence of infection, trauma, or stress.
         IL-6 is a potent mediator of inflammatory processes, and it has
been proposed that the age associated increase in IL-6 accounts for the
phenotypic changes of advanced age, particularly those that resemble
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chronic inflammatory disease (decreased lean body mass, osteopenia,
low grade anemia, decreased serum albumin and cholesterol, and
increased inflammatory proteins such as C-reactive protein  and serum
amyloid A).
The age-associated rise in IL-6 has been linked to
lymphoproliferative disorders, multiple myeloma, osteoporosis, and
Alzheimer’s disease.  Higher circulating levels of IL-6 predict disability
onset in older persons. This may be attributable to a direct effect of IL-6
on muscle atrophy and to the pathophysiologic role played by IL-6 in
specific diseases.40.
Function
          IL-6 is one of the most important mediators of fever and of the
acute phase response. It is capable of crossing the blood brain barrier
and initiating synthesis of PGE2  in the hypothalamus, thereby changing
the body's temperature.  In the muscle and fatty tissue IL-6 stimulates
energy mobilization which leads to increased body temperature.
      IL-6 can be secreted by macrophages in response to specific
microbial molecules, referred to as pathogen associated molecular
patterns (PAMPs). These PAMPs bind to highly important group of
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detection molecules of the innate immune system, called pattern
recognition receptors (PRRs), including Toll like receptors (TLRs).
These are present on the cell surface and intracellular compartments and
induce intracellular signaling cascades that give rise to inflammatory
cytokine production.
       Inhibitors of IL-6 (including estrogen) are used to treat
postmenopausal osteoporosis. IL-6 is also produced by adipocytes and is
thought to be a reason why obese individuals have higher endogeneous
levels of CRP.
Role in disease
IL-6 is elevated in  many disease processes such as diabetes,
atherosclerosis,  depression, Alzheimer's Disease, systemic lupus
erythematosus, prostate cancer, and rheumatoid arthritis. Advanced
cancer patients have higher levels of IL-6 in their blood. Hence there is
an interest in developing anti-IL-6 agents as therapy against many of
these diseases41.
Treatment
1. Tocilizumab  which has been approved for rheumatoid arthritis.
2. ALD518, is in clinical trials.42
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FRALITY
          As the aging population increases rapidly worldwide, caring for
frail older adults has become the mandate of modern medicine. As such,
frailty has been increasingly recognized as an important geriatric
syndrome43.
            The prevalence of frailty is high with  ranging from 10% to 25%
of persons age 65 years and olders. 30% to 45% over the age 85 years44.
           Frailty is characterized by decreased functional and physiologic
reserve, increased vulnerability to stressors, as well as high risk for
serious adverse health outcomes including disability, dependency, and
mortality43.
          The domains of frailty include poor nutritional status, reduced
muscle strength, diminished lower-extremity performance, low physical
activity and a sense of exhaustion45.
      Frail older adults demonstrate dysregulations in multiple
physiologic systems43. Low grade, chronic systemic inflammation
manifested in older adults, so-called “inflamm-aging,” is an important
feature of immunosenescence43.
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         Activation of the inflammation system marked by elevated levels
of inflammatory markers, above and beyond age-related increases, is
considered the most prominent pathophysiological feature of frailty1.
Sarcopenia or loss of muscle mass with aging is central manifestation of
frailty. Associated with decline in lean body mass44.
        Elevated CRP and  IL-6 are associated with increased mortality in
elderly. IL-6 has been associated with high risk of mobility disability45.
Sarcopenia
             A central factor in the pathophysiology of frailty Sarcopenia is
the age-related loss of muscle mass 46. It is derived from the Greek
‘‘sarx’’ for flesh and ‘‘penia’’ for loss. It has become conventional to
consider an older person to be sarcopenic when the lean body mass is
less than two standard deviations of the sex-specific mean in a young
healthy sample. This is defined using the  formula derived from
measurements using dual-energy x-ray absorptiometry: Appendicular
skeletal mass/height2.
         These measurements fails to take into account the quality of
muscle and with aging there can be a marked uncoupling of muscle
cross-sectional
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area and muscle fiber strength. Also, there has been increased awareness
recently that with aging there is fat accumulation in muscle
(myosteatosis), which results in a decline in muscle function.
         Using this definition, the prevalence of sarcopenia is
approximately 12% for adults 60 to 70 years of age rising to 30% by 80
years of age.
         In most studies, the development of sarcopenia is associated
strongly with increased disability, gait and balance disorders and
mortality 47,48. Muscle strength also declines with aging 49.
The causes of sarcopenia.
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The frailty cascade
Adequate nutrition
              Exercise
 Mental activity
           Socialization
 Disease process
            e.g. anemia, heart failure
       Recovery
     Age Related Physiological Deterioration
+
Frailty
Functional
Decline
Stressfull event
E.g. Influenza
Death of spouse
 Fall
Recovery
    Disability
Institutionalization
   Hospitalization
Death
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FRIED’S crieteria for frailty50
1. Gait speed
If a person takes  >6 to 7seconds to walk a distance of 15 feet, it is
considered as slow gait speed.
2. Hand grip  strength
Hand grip is measured by hand dynamometer. The participant is
asked to stand up and hold the dynamometer in the dominant hand with
the arm parallel to the body without  sqeezing the arm against the body.
Three reading was taken, best score is used. Hand grip strength was
expressed in kilogrammes (kg). Score <30 in male and <18 in female is
considered as having  low hand grip strength.
3. Weight loss
Weight loss of >5% of total body weight in last one year.
4. Physical activity
Low physical activity in the past three months.
5. Self reported physical exhaustion
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Score:
Zero = No frailty
1 and 2 = Prefrail
3 and more than three = frailty
Importance of Hand grip strength
Poor hand grip strength predicts accelerated dependency in ADL
and cognitive decline in older adults. Measuring hand grip strength can
be useful to identify those old patients at risk for future decline. Hand
grip strength measurement is an easy to use instrument in clinical
geriatric practice51.
Preventing Frailty
Food:  maintain intake
      Resistance exercises
      Atherosclerosis: prevent
      Isolation: avoid (i.e., go out and do things)
      Limit pain
      Tai Chi or other balance exercises
      Yearly check for testosterone deficiency
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Treating of Frailty
1. Frailty should be seen as treatable  and as an important stage on the
road to disability and serious illness52.
2. The first step is treat any diseases that are causing or contributing to
frailty.
3.   All  frail  person  should  be  screened  for   Depression  .  If  they  are
depressed they should be treated.
4.  Resistance exercise is another cornerstone of the management of
frailty.  resistance exercise training at least three times per week.
5.  Testosterone level should be  measured, if it is low, testosterone
replacement therapy should be started.
6. Frail elderly people should be checked for hypothyroidism. folate,
vitamin B12 and vitamin B6 supplements may be usefull.
7.  Early cognitive impairment may respond to cholinesterase inhibitors.
8.  Balance and flexibility exercises. Tai Chi  an ancient Chinese exercise
form  is also an excellent set of exercises to improve balance and
reduce falls.
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COMORBID ILLNESS
Chronic inflammation as been implicated as predictor and
contributor of aging and age associated diseases.
         Association of cardiovascular diseases and elevated of
inflammatory markers is well known.
         Inflammatory markers are elevated in diseases primarily
associated with aging like DM, SHT, CHD, CVA, Dementia, Frailty,
Osteoarthritis, Osteoporosis, Rheumatoid Arthritis.
CORONARY HEART DISEASE
          Inflammation is an immune response to injury. Inflammation
play a role in cardiovascular disease. Studies have shown an association
between high levels of markers of inflammation in the circulation with a
greater risk of a cardiovascular event.
         A critical inflammatory marker is C-reactive protein. This marker
indicates an increased risk for destabilized atherosclerotic plaque and
abnormal arterial clotting. When arterial plaque becomes destabilized, it
can burst open and block the flow of blood through a coronary artery,
resulting in an acute heart attack. New England Journal of Medicine
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studies showed that  people with high levels  of  C-reactive protein were
almost three times as likely to die from a heart attack (Ridker et al.
1997).
           In coronary heart disease hsCRP, IL-6, TNF-?,  homocysteine,
and fibrinogen are elevated.
Inflammation markers linked more with fatal than nonfatal
cardiovascular events in elderly53.
 Three  inflammatory markers—interleukin-6 , C-reactive protein
and fibrinogen—were each more strongly associated with fatal
cardiovascular events than with non-fatal cardiovascular events. Of all
three inflammatory markers, and in particular IL-6, were more strongly
associated with a fatal heart attack or stroke than with a non-fatal heart
attack or stroke.
           Whether it was useful to include these markers in tools designed
to distinguish between individuals with a high and a low risk of heart
attacks, strokes and other cardiovascular events. whether the application
of inflammatory markers may help better predict the risk of deaths from
cardiovascular disease, and whether novel treatments which dampen
inflammation might help prolong life.
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Interleukin-6 strongest CVD risk predictor in the elderly
The inflammatory markers C-reactive protein, tumor necrosis
factor-?, and interleukin-6  are independent predictors of cardiovascular
events in the elderly. All three markers, especially IL-6, predicted all
cardiovascular events more strongly than traditional risk factors.
        "Increased IL-6 level was the strongest and most consistent risk
factor for cardiovascular events" IL-6 was found to have  two to fivefold
increase in cardiovascular events54.
         Most studies on inflammatory markers have been done in younger
people and were primarily focused on CRP. Thus IL-6 and TNF-? could
serve as warning signs, because they increase early in inflammation,
whereas CRP increases later in the process.
 "Perhaps with these measures, we can go deeper into the
evaluation of cardiovascular health of the subject, and detect disease that
has not yet been diagnosed." However, assessments of IL-6 and TNF-?
are more difficult and costly compared with CRP measurements.
            The Life Extension Foundation long ago advised members to
have an annual C-reactive protein blood test to detect systemic
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inflammation that could increase the risk of heart attack, stroke, cancer
and a host of age-related diseases.
         In fact, on January 28, 2003, the American Heart Association and
Centers for Disease Control & Prevention jointly endorsed the
C-reactive protein test to screen for coronary-artery inflammation to
identify those at risk for heart attack.
The American Heart Association and US Centers for Disease Control
and Prevention have defined risk groups as follows:
? Low risk:  less than 1.0 mg/L
? Average risk: 1.0 to 3.0 mg/L
? High risk:  above 3.0 mg/L
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DIABETES MELLUTUS
        In recent years, it has been theorized that chronic, low-grade tissue
inflammation related to obesity contributes to insulin resistance, the
major cause of Type 2 diabetes.
        The baseline levels of C-reactive protein and interleukin-6  were
significantly higher among those who subsequently developed
diabetes55.
          "Elevated C-reactive protein and IL-6 predict the development of
Type II diabetes mellitus. These data support a possible role for
inflammation in diabetogenesis."
          A low-grade inflammation precedes and predicts diabetes
development in adults participating in the Atherosclerosis Risk in
Communities  Study 56.
        Several reports in various markers of inflammation  in different
population groups have confirmed the association of inflammation in
diabetes57-65.
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Hypertension
The role of inflammation in development of hypertension
 Elevated hsCRP appeared to be predictive for the development of
future hypertension in apparently normotensive individuals, which
might suggest that inflammation even precedes the subsequent
development of hypertension 66.
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CEREBRO VASCULAR ACCIDENTS
         Markers of inflammation, including peak plasma CRP, WBC
count, ESR or plasma cortisol, were associated with severity of stroke,
CT brain infarct volume or clinical outcome67,68.
DEMENTIA
         Inflammation has been involved in the pathogenesis of dementia.
The study evaluates the presence and the source of pro- and anti-
inflammatory cytokines in the blood of patients with Alzheimer's
disease , multi-infarct dementia 69. The combination  of  high  CRP and
high IL6 was associated with risk of  Vascular dementia70.
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Age group
Group Frequency Percent
Comorbid 75 - 80 years 28 93.3
81 - 90 years 2 6.7
Total 30 100.0
Frailty 75 - 80 years 23 76.7
81 - 90 years 6 20.0
91 or more 1 3.3
Total 30 100.0
Healthy elders 75 - 80 years 28 93.3
81 - 90 years 2 6.7
Total 30 100.0
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Gender distribution
Gender distribution
Female
37%
Male
63%
Gender
Frequency Percent
Male 57 63.3
Female 33 36.7
Total 90 100.0
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Gender distribution by Group
Male Female
Gender
Group Frequency Percent
Comorbid Male 19 63.3
Female 11 36.7
Total 30 100.0
Frailty Male 17 56.7
Female 13 43.3
Total 30 100.0
Healthy elders Male 21 70.0
Female 9 30.0
Total 30 100.0
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SMOKING
Frequency Percent
No 64 71.1
Yes 26 28.9
Total 90 100.0
Group wise Frequency Table
SMOKING
Group Frequency Percent
Comorbid No 23 76.7
Yes 7 23.3
Total 30 100.0
Frailty No 22 73.3
Yes 8 26.7
Total 30 100.0
Healthy elders No 19 63.3
Yes 11 36.7
Total 30 100.0
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COMORBID ILLNESS
Diabetes   Mellitus
Frequency Percent
No 16 53.3
Yes 14 46.7
Total 30 100.0
Systematic Hypertension
Frequency Percent
No 10 33.3
Yes 20 66.7
Total 30 100.0
Coronary heart  disease
Frequency Percent
No 22 73.3
Yes 8 26.7
Total 30 100.0
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Stroke
Frequency Percent
No 24 80.0
Yes 6 20.0
Total 30 100.0
Dementia
Frequency Percent
Normal          25 83.3
Dementia 5 16.7
Total 30 100.0
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FRAILTY
Frequency Percent
Pre frail 6 20.0
Frailty 24 80.0
Total 30 100.0
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CRP level   Group
Group
TotalComorbid Frailty
Healthy
elders
CRP
level
Elevated Count 30 30 30 90
% within Group 100.0% 100.0% 100.0% 100.0%
Total Count 30 30 30 90
% within Group 100.0% 100.0% 100.0% 100.0%
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IL-6 level * Group
Group
TotalComorbid Frailty
Healthy
elders
IL-6
level
Normal Count 3 2 9 14
% within Group 10.0% 6.7% 30.0% 15.6%
Elevated Count 27 28 21 76
% within Group 90.0% 93.3% 70.0% 84.4%
Total Count 30 30 30 90
% within Group 100.0% 100.0% 100.0% 100.0%
Chi-Square Value: 7.274 P – Value: 0.026 Significant
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DISCUSSION
            In this study inflammatory markers C-Reactive protein and
Interleukin-6 of 90 elderly patients were analysed, under the three
groups namely healthy elders, frail elders and elders with comorbid
illness.
           Among them 63% are males and 37% are females. In healthy
elders 19 are male and 11 are female. In frailty group 17 are male and 13
are female. In elders with comorbid illness 21 are male and 9 are female.
          The  age  distribution  was  89%  in  age  group  of   75  to  80  years.
10% in age group of  81 to 90 years. Remaining 1% in age group of
>90 years. More number of patients were found in age group of 75 to 80
years.
            In the study group 28.9%  were  smokers  and 71.1% were  non
smokers. C-Reactive protein levels are elevated in smokers as well as
non smokers in all the three groups. Hence it is not a significant
association. Where as Interleukin-6 levels are more elevated  in smokers
in healthy elders and elders with comorbid illness, than non smokers of
the same groups.
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           In the comorbid group, diabetes was detected in 14, systemic
hypertension in 20, Coronary heart disease in 8, stroke in 6 and
dementia in 5 patients. CRP level are elevated in all the patients.
Interleukin-6 level are elevated more in diabetic and coronary heart
disease  patients.
           In the frailty group 6 were Pre frail  and 24 were frail.   CRP are
elevated in both Pre frail and frail group.  Interleukin-6 was elevated,
more in frail group than in Pre frail group.  83% of patients in Pre frail
group, and 96% of patients in frail group had elevated level of
interleukin-6.
CRP levels are elevated in all the 3 groups.  The mean CRP level
was 63.7 in healthy elders, 89 in Frail elders, 99.3 in elders with
comorbid illness.  CRP is 10 fold increased in healthy elders, 15 fold
increased in frail elders, 16.5 folds increased in elders with comorbid
illness. Thus the patients with comorbid illness have higher CRP level.
In healthy elders 21(70%) have  elevated level of interleukin-6.
In frail elders 28(93%) have elevated level of interleukin-6.
In comorbid illness 27 (90%)have elevated level of interleukin-6.
59
The mean interleukin-6 level was 6.6 in healthy elders, 11.4 in
frail group, 5.5 in comorbid illness.  Interleukin-6 is 3 fold increased in
healthy elders, 6 fold in frail elders and 2.75 fold increased in elders
with comorbid illness.  Thus in frail elders interleukin-6 is more
elevated.
In summary CRP level are elevated in all the three groups.
In patients with comorbid illness CRP levels are higher compared with
other two groups.  Interleukin-6 level are elevated more in  diabetes and
coronary heart disease  patients.  Interleukin-6 is more elevated in frail
elders.
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CONCLUSION
1.  CRP levels are elevated in all patients age more than 75 years.
2.  Elders with comorbid illness have higher CRP level, compared to
healthy groups.
3.  Interleukin-6 levels are elevated in smokers, both in healthy
group and in comorbid group.
4.  Interleukin-6 level are elevated more in diabetic and coronary
heart disease  patients.
5.  Interleukin-6 was elevated more in frail group than in Pre frail
group.
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PROFORMA
Name
Age
Sex
IP/OP No
C/O
Co/morbid illness
History Duration Treatment
DM
SHT
CAHD
CVA
Dementia
Personal H/O:
Smoker
Alcoholic
General Examination
BP
PR
Systemic Examination
Mini mental score
Score
FRIED’S crieteria for frailty:
1.Gait speed :
2.Hand grip  strength  :
3.Weight loss :
4.Physical activity  :
5.Self reported physical exhaustion :
Score:
Investigation:
ESR Hemoglobin Bloodsugar Urea Creatinine
Lipid
profile
ECG
CXR-PA
CT Brain
IL-6
CRP
Impression: 1.Healthy elder 2.Frail elder 3.Elders with comorbid illness.
ELDERLY WITH COMORBID ILLNESS
No Age Sex DM SHT CHD CVA
Deme
ntia
Duration
Smo-
king
Alcohol
1 75 M No Yes No No No  10yrs No No
2 88 M No Yes No No No 3yrs No No
3 77 M Yes Yes No No No DM
1&1/2yrs,
SHT 8yrs
Quit
30yrs
Yes
4 82 M No No No Yes No 2yrs Quit
10Yrs
Quit
10 Yrs
5 79 M Yes No Yes No No 20yrs Quit
15yrs
Yes
6 80 M Yes Yes No No No DM
2months
SHT
10yrs
No No
7 77 M No Yes No No No 3yrs No No
8 76 M No Yes No No 10yrs No No
9 75 F Yes Yes No No No DM 15yrs
SHT
4months
No No
10 80 M No Yes Yes No No 20yrs No Yes
11 75 M No No No Yes No 1 week No No
12 80 M No Yes No No No 5yrs Quit
15yrs
Quit
3Yrs
13 75 M Yes Yes No Yes No 10yrs No Yes
14 80 M Yes Yes No No No 20yrs No No
15 80 M No Yes Yes No No 10yrs Quit
25yrs
Quit
25Yrs
16 78 F Yes Yes Yes No No 10yrs No No
17 78 F No Yes No No No 20yrs No No
18 75 F No Yes No No 2yrs No No
19 75 F Yes Yes No No No DM
6months
SHT 4yrs
No No
No Age Sex DM SHT CHD CVA
Deme
ntia
Duration
Smo-
king
Alcohol
20 75 F Yes Yes No No No 2yrs No No
21 75 F Yes Yes No No No 5yrs No No
22 80 M No Yes No No No 10yrs No No
23 78 F No Yes No No No 10yrs No No
24 75 F Yes Yes No No No 10yrs No No
25 75 M Yes Yes Yes No No 20yrs Quit
20Yrs
Quit
20Yrs
26 75 F No No No Yes No 1yrs No No
27 78 M No Yes No Yes Yes 10yrs No No
28 75 M Yes No No No No 25yrs Yes Yes
29 75 M No No Yes No No 3yrs Yes No
30 75 F No No No Yes No 10yrs No No
FRAIL ELDERS
No Age Sex DM SHT CHD CVA Dementia Duration smoking Alcohol
31 96 M No No No No No No No No
32 80 F No No No No No No No No
33 75 F No No No No No No No No
34 76 M No No No No No No Quit
5Yrs
No
35 89 M No No No No No No No No
36 75 M No No No No No No No No
37 80 F No No No No No No No No
38 80 M No No No No No No No No
39 76 M No No No No No No Quit
20Yrs
No
40 88 F No No No No No No No No
41 81 M No No No No No No Yes No
42 76 M No No No No No No Quit
30Yrs
Quit
40Yrs
43 75 F No No No No No No No No
44 83 M No No No No No No Yes No
45 80 M No No No No No No Yes Quit
2Yrs
46 75 M No No No No No No No No
47 90 M No No No No No No Yes No
48 75 M No No No No No No No No
49 75 M No No No No No No No No
50 81 M No No No No No No No No
51 76 M No No No No No No No Quit
10Yrs
52 80 F No No No No No No No No
53 75 F No No No No No No No No
54 80 F No No No No No No No No
55 75 F No No No No No No No No
56 75 F No No No No No No No No
57 80 F No No No No No No No No
58 75 F No No No No No No No No
59 75 F No No No No No No No No
60 75 M No No No No No No Quit
1Yr
Quit
1Yr
HEALTHY ELDERS
No Age Sex DM SHT CHD CVA DEMENTIA Duration Smoking Alcohol
61 80 M No No No No No No No No
62 75 M No No No No No No No No
63 75 M No No No No No No No No
64 75 F No No No No No No No No
65 76 F No No No No No No No No
66 80 F No No No No No No No No
67 75 F No No No No No No No No
68 79 F No No No No No No No No
69 76 F No No No No No No No No
70 76 F No No No No No No No No
71 75 M No No No No No No No No
72 75 M No No No No No No No No
73 75 M No No No No No No No No
74 75 M No No No No No No Quit
5Yrs
No
75 76 M No No No No No No Quit
10Yrs
No
76 80 M No No No No No No Quit
20Yrs
Quit
20Yrs
77 75 M No No No No No No No No
78 75 F No No No No No No No No
79 75 M No No No No No No Quit
10Yrs
No
80 75 M No No No No No No Quit
5Yrs
Quit
5Yrs
81 75 M No No No No No No Quit
5Yrs
Quit
5Yrs
82 78 F No No No No No No Quit
1yr
No
83 75 M No No No No No No No No
84 83 M No No No No No No Quit
15Yrs
No
85 84 M No No No No No No Quit
40Yrs
No
86 80 M No No No No No No No No
87 80 M No No No No No No Quit
2Yrs
Quit
2Yrs
88 75 M No No No No No No Quit
10Yrs
Quit
10Yrs
89 75 M No No No No No No No No
90 80 M No No No No No No No No
ELDERLY WITH COMORBID ILLNESS
No MMSE Educa
tion
Frailty
Score
Hb ESR Blood
Sugar
Urea Creatinine Total
Chosterol
TGL HDL
1 27/30 7th std 0/5 12.6 22 122 26 .9 148 72 38
2 27/30 8th std 0/5 11.2 38 136 24 1 162 82 51
3 29/30 9th std 0/5 11.5 50 75 40 .9 171 105 42
4 9/30 6th std 3/5 11.6 16 94 32 1 160 110 45
5 28/30 9th std 0/5 11.7 22 233 43 1.4 152 121 36
6 29/30 8th std 2/5 11.6 18 185 21 .7 162 113 40
7 29/30 6th std 0/5 8 47 86 49 1 198 84 50
8 30/30 SSLC 0/5 11.8 52 78 22 .9 200 82 30
9 28/30 5th std 4/5 11.2 17 252 30 .9 161 95 43
10 30/30 6th std 0/5 10 15 86 24 .9 205 136 36
11 27/30 8th std 2/5 9.9 30 94 30 2.2 206 110 39
12 28/30 6th std 0/5 13.7 25 103 30 1.0 259 193 56
13 21/30 illiterat
e
2-5 11.9 45 93 25 .9 149 136 34
14 28/30 BSc 0/5 12.5 10 114 24 .9 154 88 39
15 29/30 SSLC 1/5 11.7 45 118 32 1.3 145 119 35
16 25/30 5th std 2/5 10 22 204 22 .9 236 278 55
17 28/30 illiterat
e
0/5 11.7 25 139 29 .8 208 128 48
18 22/30 8th std 3/5 10.6 32 110 19 .9 170 136 52
19 30/30 8th std 4/5 9 39 122 26 1 165 105 36
20 27/30 6th std 2/5 8.8 42 134 28 1.1 178 151 46
21 27/30 3rd std 0/5 12.8 28 142 32 1.4 226 132 40
22 27/30 SSLC 0/5 12 21 132 30 1.1 158 129 42
23 30/30 SSLC 0/5 9.1 32 106 32 1.0 192 126 38
24 30/30 SSLC 1/5 8.8 36 162 34 1.1 158 148 42
25 25/30 6th
std
2/5 8.6 18 191 19 1 152 100 35
26 26/30 6th
std
2/5 11.1 28 106 18 .9 212 136 48
27 16/30 Advoc
ate
3/5 11.6 29 116 22 1.1 188 162 52
28 27/30 SSLC 2/5 12.8 21 136 32 1.3 182 161 39
29 30/30 SSLC 0/5 13.1 18 111 31 1.2 161 138 28
30 3/30 SSLC 0/5 12.8 18 109 34 1.4 156 142 40
FRAIL ELDERS
No MMSE
Edu-
cation
Frailty
Score
Hb ESR
Blood
Sugar
Urea
Creatin
ine
Total
cholesterol
TGL HDL
31 18/30 4th std 5/5 10 20 72 46 1.3 192 121 37
32 27/30 illiterate 3/5 10.8 18 101 28 .9 169 132 36
33 26/30 illiterate 5/5 11 21 108 28 1.1 162 156 39
34 30/30 SSLC 3/5 10.4 29 95 28 1 179 261 40
35 28/30 SSLC 3/5 11 29 74 25 .9 143 71 35
36 28/30 8th std 4/5 13.1 86 90 36 1.1 158 80 45
37 24/30 7th std 5/5 10.2 7 88 28 .9 270 120 36
38 28/30 8th std 3/5 12 25 98 28 .7 175 268 45
39 29/30 9th std 4/5 7.6 65 126 37 1.4 142 74 36
40 26/30 illiterate 5/5 11 16 128 26 .8 281 150 36
41 28/30 8th std 4/5 11.1 84 79 45 1.5 149 120 34
42 28/30 8th std 1/5 9 8 82 35 1 124 181 38
43 30/30 SSLC 2/5 9.6 22 121 19 .9 156 131 38
44 27/30 SSLC 5/5 10.4 66 89 27 1 167 80 36
45 28/30 5th std 5/5 11.8 30 93 26 1 152 144 30
46 25/30 6th std 1/5 9.6 9 96 41 1.1 146 72 42
47 14/30 illiterate 5/5 10.1 15 106 45 1.4 210 110 38
48 18/30 7th std 4/5 13.7 105 81 21 1.8 178 132 36
49 26/30 7th std 5/5 6.2 88 96 38 1.1 142 137 38
50 25/30 7th std 4/5 10.6 136 111 39 1.2 153 84 46
51 30/30 8th std 3/5 11.1 16 112 28 1 206 179 42
52 27/30 6th std 3/5 8.9 28 121 28 .9 205 126 48
53 30/30 8th std 3/5 12 32 82 28 .9 161 96 36
54 29/30 SSLC 3/5 12.6 32 72 30 1 162 136 38
55 29/30 7th std 3/5 11.6 31 116 28 1.4 161 146 39
56 26/30 illiterate 4/5 8.9 32 142 28 1.1 156 148 40
57 22/30 illiterate 5/5 8.4 54 92 26 1 196 120 39
58 27/30 6th std 2/5 12.6 32 126 29 .9 156 144 40
59 29/30 7th std 2/5 8.9 18 132 29 .9 151 148 40
60 23/30 illiterate 2/5 9.3 10 117 22 1 145 167 37
HEALTHY ELDERS
No MMSE
Edu-
cation
Frailty
Score
Hb ESR
Blood
Sugar
Urea
Creati
nine
Total
Chol-
esterol
TGL HDL
61 30/30 BE 0/5 11.9 13 90 38 1.1 189 116 36
62 30/30 SSLC 0/5 9.8 18 121 32 1.2 169 136 36
63 27/30 4th std 0/5 10.6 13 89 28 1.2 189 126 38
64 27/30 6th std 0/5 8.9 29 189 32 1.1 144 72 36
65 29/30 4th std 0/5 10.1 26 106 29 .9 146 126 36
66 30/30 7th std 0/5 9.2 22 89 32 1.1 142 221 42
67 26/30 illiterate 0/5 9.8 31 136 31 1.4 156 144 36
68 29/30 7th std 0/5 8.9 42 156 29 1.1 210 72 36
69 30/30 5th std 0/5 10.6 86 116 29 1.1 149 119 35
70 29/30 8th std 0/5 12 26 126 32 1.1 138 108 34
71 28/30 7th std 0/5 13 26 106 28 .9 158 132 38
72 28/30 5th std 0/5 11 42 98 32 .9 178 140 38
73 30/30 SSLC 0/5 8.8 23 103 30 1 176 128 38
74 29/30 8th std 0/5 9.2 32 106 32 .9 192 136 32
75 27/30 6th std 0/5 11.9 28 89 32 1.1 189 136 31
76 29/30 8th std 0/5 12.3 52 89 33 1.2 212 136 30
77 28/30 9th std 0/5 11 10 118 23 .9 162 136 36
78 27/30 6th std 0/5 8.9 22 106 33 1.3 152 146 38
79 27/30 6th std 0/5 9.2 32 134 32 .7 132 162 34
80 24/30 illiterate 0/5 8.3 46 134 42 1.4 112 156 56
81 26/30 illiterate 0/5 9.8 34 109 31 1.1 142 192 48
82 29/30 illiterate 0/5 10.2 15 83 18 .7 232 201 48
83 30/30 9th std 0/5 13 11 88 25 .9 226 75 30
84 30/30 8th std 0/5 9 60 72 30 .9 193 87 33
85 27/30 8th std 0/5 7.9 48 99 29 .9 172 131 39
86 29/30 6th std 0/5 11 45 81 20 .6 210 106 52
87 28/30 1st std 0/5 11.6 17 135 21 .7 131 158 38
88 30/30 6th std 0/5 10.5 11 86 24 .8 199 182 33
89 28/30 Teacher 0/5 11 75 68 27 .9 161 136 38
90 29/30 8th std 0/5 12.1 21 106 148 151 40
ELDERLY WITH COMORBID ILLNESS
No ECG CXP-PA CT Brain CRP IL-6
1 NSR, WNL Normal Right MCA
infarct
 120 6
2 NSR, incomplete
RBBB
Aortic knuckle prominent -- 90 4
3 NSR, WNL Unfolding of Aorta,
Cardiomegaly
-- 90 6
4 AF, CVR Cardiomegaly Bilateral
MCA infarct
150 4
5 Sinus tachycardia,
old IWMI
Increased
bronchovascular
marking
-- 90 3
6 NSR, LVH Bilateral hilar opacity -- 190 5
7 NSR, LVH LV Configuration -- 90 3
8 Poor recording Bilateral hilar opacity -- 90 4
9 NSR, WNL Cardiomegaly, LV
Configuration
-- 190 10
10 NSR,  incomplete
RBBB
Normal -- 190 10
11 NSR, WNL Normal Right MCA
infarct
50 1
12 NSR, WNL Rt Costo phrenic angle
obliteration
-- 50 4
13 NSR, LVH Aortic knuckle prominent Left MCA
infarct
70 6
14 NSR, WNL Right hilar Opacity -- 80 3
15 NSR, WNL Normal -- 190 10
16 2nd degree AV block,
mobitz type II
Cardiomegaly -- 90 3
17 LBBB Increased
bronchovascular
marking, Aortic knuckle
prominent
-- 70 1
18 NSR, WNL Normal -- 90 6
19 NSR, WNL Cardiomegaly -- 90 4
20 NSR, WNL Normal -- 80 6
ELDERLY WITH COMORBID ILLNESS
No ECG CXR-PA CT Brain CRP IL-6
21 NSR, WNL LV Configuration -- 90 6
22 NSR, WNL Normal -- 60 8
23 NSR, LAD Normal -- 190 6
24 NSR, LVH Strain LV Configuration -- 80 6
25 NSR, PPRW Normal -- 50 6
26 NSR, WNL Normal Right MCA
infarct
90 5
27 NSR, LVH Cardiomegaly Multi infarct 80 2
28 NSR, WNL Normal -- 50 6
29 Old IWMI Normal -- 50 15
30 NSR, WNL Normal Multi infarct 90 6
FRAIL ELDERS
No ECG CXR-PA CT Brain CRP IL-6
31 NSR, WNL Normal -- 90 4
32 NSR, WNL Unfolding of Aorta -- 190 4
33 NSR, WNL Normal -- 80 8
34 NSR, LAD,LVH Bilateral hilar Opacity -- 50 6
35 NSR, WNL Aortic knuckle
prominent
-- 50 4
36 NSR, WNL Increased broncho
Vascular marking
-- 80 5
37 NSR, WNL Unfolding of Aorta -- 90 25
38 LAD, RBBB Normal -- 90 6
39 NSR, LAD, old
IWMI
Cardiomegaly -- 90 10
40 NSR, WNL Normal -- 90 10
41 NSR, WNL Normal -- 50 5
42 NSR, WNL Normal -- 70 2
43 NSR, WNL LVH configuration -- 190 30
44 NSR, WNL Tubular heart,
emphysematous
chest
-- 90 2
45 NSR, WNL Normal -- 70 25
46 NSR, WNL Normal -- 50 3
47 NSR, WNL Normal -- 30 10
48 NSR, WNL Normal -- 50 15
49 ST Normal -- 190 10
50 NSR, WNL Normal -- 90 5
51 NSR,WNL Normal -- 70 5
52 NSR,WNL Normal -- 190 20
53 NSR,WNL Normal -- 90 20
54 NSR,T wave
Inversion in V1,V2
Normal -- 80 20
55 NSR,LAD, old
IWMI
Normal -- 60 25
56 NSR, incomplete
RBBB
Unfolding of aorta -- 90 10
57 NSR, PPRW Increased Broncho
vascular marking
-- 90 15
58 Sinus Arrhythmia Normal -- 110 4
59 NSR, LVH LVH configuration -- 60 4
60 NSR, WNL Left hilar opacity -- 50 30
HEALTHY ELDERS
No ECG CXR-PA CT Brain CRP IL-6
61 NSR, WNL Increased
bronchovascular
marking
-- 50 15
62 NSR, PPRW Rt hilar opacity present -- 30 20
63 NSR, Incomplete
RBBB
Normal -- 50 4
64 Sinus arrhythmia Increased
bronchovascular
marking
-- 90 2
65 NSR, WNL Normal -- 80 4
66 NSR, WNL Aortic knuckle
prominent
-- 110 2
67 NSR, WNL Normal -- 30 2
68 NSR, PPRW Normal -- 90 3
69 NSR, WNL Increased
bronchovascular
marking
-- 50 4
70 NSR, WNL Normal -- 60 4
71 NSR, WNL Normal -- 90 2
72 NSR, WNL Aortic knuckle
prominent
-- 40 2
73 NSR, WNL Normal -- 60 20
74 NSR, PPRW Normal -- 80 8
75 NSR, WNL Normal -- 90 8
76 NSR, WNL Increased
bronchovascular
marking
-- 90 2
77 NSR, WNL Normal -- 40 5
78 NSR, WNL Increased
bronchovascular
marking
-- 90 10
79 NSR, WNL Normal -- 30 10
80 NSR, WNL Normal -- 50 5
81 Incomplete RBBB Normal -- 40 5
82 NSR, PPRW Normal -- 90 25
83 NSR, WNL Unfolding of aorta -- 70 2
84 Occasional atrial
Ectopics present
Increased
bronchovascular
marking
-- 40 4
85 NSR, WNL Normal -- 70 4
86 NSR, WNL Normal -- 90 1
87 NSR, WNL Normal -- 50 2
88 NSR, WNL Normal -- 40 10
89 NSR, WNL Normal -- 70 10
90 NSR, WNL Normal -- 50 4

